Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Porgaviximab - Mapp Biopharmaceuticals

Next Previous
Drug Profile

Porgaviximab - Mapp Biopharmaceuticals

Alternative Names: Anti-Ebola monoclonal antibody - Mapp Pharmaceuticals; anti-EBOV-c2G4; c2G4-N; ZMapp

Latest Information Update: 23 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mapp Biopharmaceutical; Public Health Agency of Canada
  • Developer Mapp Biopharmaceutical; National Institute of Allergy and Infectious Diseases
  • Class Antivirals; Monoclonal antibodies; Recombinant fusion proteins; Recombinant proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Ebola virus infections

Most Recent Events

  • 23 Dec 2022 Discontinued - Phase-I/II for Ebola virus infections in Guinea (IV) (Mapp Biopharmaceutical pipeline, December 2022)
  • 23 Dec 2022 Discontinued - Phase-I/II for Ebola virus infections in Liberia (IV) (Mapp Biopharmaceutical pipeline, December 2022)
  • 23 Dec 2022 Discontinued - Phase-I/II for Ebola virus infections in Sierra Leone (IV) (Mapp Biopharmaceutical pipeline, December 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top